Observational studies of the effectiveness of vaccines to prevent COVID-19 are needed to
inform real-world use. Such studies are now underway amid the ongoing rollout of SARS …

Controlled human infection (CHI) trials, in which healthy volunteers are experimentally
infected, can accelerate the development of novel drugs and vaccines for infectious …

This report compiles and summarizes all published recommendations from CDC's Advisory
Committee on Immunization Practices (ACIP) for use of pneumococcal vaccines in adults …

T cells can contribute to clearance of respiratory viruses that cause acute-resolving
infections such as SARS-CoV-2, hel** to provide long-lived protection against disease …

Background While secondary pneumococcal pneumonia occurs less commonly after
coronavirus disease 2019 (COVID-19) than after other viral infections, it remains unclear …

The timelines for develo** vaccines against infectious diseases are lengthy, and often
vaccines that reach the stage of large phase 3 field trials fail to provide the desired level of …

Are antibodies important for protection against tuberculosis? The jury has been out for more
than 100 years. B cell depletion in experimental Mycobacterium tuberculosis infection failed …

Objectives Despite the current pneumococcal vaccination program in England for older
adults and adults with underlying conditions, disease burden remains high. We evaluated …

Background The effect of childhood pneumococcal conjugate vaccine implementation in
Malawi is threatened by absence of herd effect. There is persistent vaccine-type …

Streptococcus pyogenes causes at least 750 million infections and more than 500,000
deaths each year. No vaccine is currently available for S. pyogenes and the use of human …